Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-β-Insensitive Cytolytic T Cells for Treatment of Established Mouse Renca Tumors

Urology

Volumn 72, Issue 4, 2008, Pages 943-947

  Qin, Weijun ^a   Tian, Feng ^a   Wang, Fuli ^a   Song, Bin ^a   Wang, He ^a   Zhang, Qiang ^a   Jovanovic, Borko ^a   Liang, Lili ^a   Guo, Yinglu ^a   Smith, Norm ^a   Lee, Chung ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ISOLATION; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; KIDNEY CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENCA TUMOR; RETROVIRUS; TUMOR GROWTH;

ANIMALS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 53149148542     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.04.017     Document Type: Article

References (15)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin. 57 (2007) 43-66
2. Gleave M.E., Elhilali M., Fradet Y., et al., Canadian Urologic Oncology Group. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med. 338 (1998) 1265-1271
3. Gitlitz B.J., and Figlin R.A. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 30 (2003) 589-600
4. Bleumer I., Oosterwijk E., De Mulder P., et al. Immunotherapy for renal cell carcinoma. Eur Urol. 44 (2003) 65-75
5. Derynck R., Akhurst R.J., and Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet. 29 (2001) 117-129
6. Pinkas J., and Teicher B.A. TGF-β in cancer and as a therapeutic target. Biochem Pharmacol. l72 (2006) 523-529
7. 1 in renal cell carcinoma. Cancer Res. 49 (1989) 6972-6975
8. Wakefield L.M., and Roberts A.B. TGF-β signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12 (2002) 22-29
9. + T cells: Eradication of autologous mouse prostate cancer. Cancer Res. 65 (2005) 1761-1769
10. + T regulatory cells: Role of tumor-derived TGF-β. J Immunol. 178 (2007) 2883-2892
11. Zhang Q., Rubenstein J.N., Liu V.C., et al. Restoration of expression of transforming growth factor-β type II receptor in murine renal cell carcinoma (Renca) cells by 5-aza-2′-deoxycytidine. Life Sci. 76 (2005) 1159-1166
12. van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 9 (1997) 684-693
13. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
14. Zeh III H.J., Perry-Lalley D., Dudley M.E., et al. High avidity CTLs for two self-antigen demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 162 (1999) 989-994
15. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppresion by TGF-β inhibitors. Invest New Drugs 21 (2003) 21-32